- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Type 2 diabetes mellitus (T2DM)
- Meeting Date: March 2026
- Public Summary Document (PSD) March 2026 PBAC Meeting - (PDF)
- Public Summary Document (PSD) March 2026 PBAC Meeting - (DOCX)
Tirzepatide – March 2026
Solution for injection 2.5 mg in 0.5 mL , vial/pre-filled pen , Solution for injection 5 mg in 0.5 mL vial/pre, filled pen , Solution for injection 7.5 mg in 0.5 mL , vial/pre-filled pen , Solution for injection 10 mg in 0.5 mL , vial/pre-filled pen , Solution for injection 12.5 mg in 0.5 mL , vial/pre-filled pen , Solution for injection 15 mg in 0.5 mL , vial/pre-filled pen , Injection 4.17 milligrams per mL (2.5 mg per , dose) in multi-dose pre-filled pen, 4 dose , Injection 8.33 milligrams per mL (5 mg per , dose) in multi-dose pre-filled pen, 4 doses , Injection 12.5 milligrams per mL (7.5 mg per , dose) in multi-dose pre-filled pen, 4 doses , Injection 16.67 milligrams per mL (10 mg per , dose) in multi-dose pre-filled pen, 4 doses , Injection 20.83 milligrams per mL (12.5 mg , per dose) in multi-dose pre-filled pen, 4 , doses , Injection 25 milligrams per mL (15 mg per , dose) in multi-dose pre-filled pen, 4 doses
